FrancophonIA/ELRC3.0 huggingface dataset:
English: Puregon 50 IU/0.5 mL solution for injection EU/1/96/008/017
Croatian: Puregon 50 IU/0,5 ml otopina za injekciju EU/1/96/008/017
English: Puregon 150 IU/0.5 mL solution for injection: Each vial contains the active substance follitropin beta, a hormone known as follicle-stimulating hormone (FSH), in a strength of 150 IU in 0.5 mL aqueous solution per vial.
Croatian: Puregon 150 IU/0,5 ml otopina za injekciju: Jedna bočica sadrži djelatnu tvar folitropin beta, hormon poznat kao folikulostimulirajući hormon (FSH) u koncentraciji od 150 IU u 0,5 ml vodene otopine po bočici.
English: Puregon 150 IU/0.5 mL solution for injection
Croatian: Puregon 150 IU/0,5 ml otopina za injekciju
English: OUTER CARTON TEXT Puregon 150 IU/0.5 mL 1, 5 or 10 vials
Croatian: TEKST NA KUTIJI - Puregon 150 IU/0,5 ml 1, 5 ili 10 bočica
English: Puregon 150 IU/0.5 mL solution for injection EU/1/96/008/026
Croatian: Puregon 150 IU/0,5 ml otopina za injekciju EU/1/96/008/026
English: One vial contains 7.5 microgram of protein (specific in vivo bioactivity equal to approximately 10,000 IU FSH / mg protein).
Croatian: Jedna bočica sadrži 7,5 mikrograma proteina (čija specifična in vivo biološka aktivnost odgovara približno 10 000 IU FSH/mg proteina).
English: Puregon 50 IU/0.5 mL solution for injection
Croatian: Puregon 50 IU/0,5 ml otopina za injekciju
English: OUTER CARTON TEXT Puregon 200 IU/0.5 mL 1, 5 or 10 vials
Croatian: TEKST NA KUTIJI - Puregon 200 IU/0,5 ml 1, 5 ili 10 bočica
English: Puregon 300 IU/0.36 mL solution for injection follitropin beta
Croatian: Puregon 300 IU/0,36 ml otopina za injekciju folitropin beta
English: Puregon 200 IU/0.5 mL injection follitropin beta
Croatian: Puregon 200 IU/0,5 ml otopina za injekciju folitropin beta
English: Puregon 150 IU/0.5 mL injection follitropin beta
Croatian: Puregon 150 IU/0,5 ml otopina za injekciju folitropin beta
English: Puregon 50 IU/0.5 mL injection follitropin beta
Croatian: Puregon 50 IU/0,5 ml otopina za injekciju folitropin beta
English: Puregon 200 IU/0.5 mL solution for injection: Each vial contains the active substance follitropin beta, a hormone known as follicle-stimulating hormone (FSH), in a strength of 200 IU in 0.5 mL aqueous solution per vial.
Croatian: Puregon 200 IU/0,5 ml otopina za injekciju: Jedna bočica sadrži djelatnu tvar folitropin beta, hormon poznat kao folikulostimulirajući hormon (FSH) u koncentraciji od 200 IU u 0,5 ml vodene otopine po bočici.
English: Puregon 100 IU/0.5 mL solution for injection
Croatian: Puregon 100 IU/0,5 ml otopina za injekciju
English: OUTER CARTON TEXT Puregon 50 IU/0.5 mL 1, 5 or 10 vials
Croatian: TEKST NA KUTIJI - Puregon 50 IU/0,5 ml 1, 5 ili 10 bočica
English: OUTER CARTON TEXT Puregon 100 IU/0.5 mL 1, 5 or 10 vials
Croatian: TEKST NA KUTIJI - Puregon 100 IU/0,5 ml 1, 5 ili 10 bočica
English: Puregon 100 IU/0.5 mL injection follitropin beta
Croatian: Puregon 100 IU/0,5 ml otopina za injekciju folitropin beta
English: Puregon 100 IU/0.5 mL solution for injection: Each vial contains the active substance follitropin beta, a hormone known as follicle-stimulating hormone (FSH), in a strength of 100 IU in 0.5 mL aqueous solution per vial.
Croatian: Puregon 100 IU/0,5 ml otopina za injekciju: Jedna bočica sadrži djelatnu tvar folitropin beta, hormon poznat kao folikulostimulirajući hormon (FSH) u koncentraciji od 100 IU u 0,5 ml vodene otopine po bočici.
English: Puregon 50 IU/0.5 mL solution for injection: Each vial contains the active substance follitropin beta, a hormone known as follicle-stimulating hormone (FSH), in a strength of 50 IU in 0.5 mL aqueous solution per vial.
Croatian: Puregon 50 IU/0,5 ml otopina za injekciju: Jedna bočica sadrži djelatnu tvar folitropin beta, hormon poznat kao folikulostimulirajući hormon (FSH) u koncentraciji od 50 IU u 0,5 ml vodene otopine po bočici.
English: Puregon 600 IU/0.72 mL solution for injection follitropin beta
Croatian: Puregon 600 IU/0,72 ml otopina za injekciju folitropin beta
English: Puregon 150 IU/0.18 mL solution for injection follitropin beta
Croatian: Puregon 150 IU/0,18 ml otopina za injekciju folitropin beta
English: Do not mix any other drug into the cartridges.Empty cartridges must not be refilled.
Croatian: U uložak ne smijete umiješati drugi lijek.
English: Further information on Rasilez HCT can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Croatian: Više informacija o lijeku Rasilez HCT možete naći na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Overall, the company presented the results of nine main studies involving a total of almost 9,000 patients with essential hypertension.
Croatian: Tvrtka je ukupno dostavila rezultate iz devet glavnih ispitivanja kojima je bilo obuhvaćeno ukupno gotovo 9 000 bolesnika s esencijalnom hipertenzijom.
English: Rasilez HCT can only be obtained with a prescription and it is available as tablets (150 mg/12.5 mg; 150 mg/25 mg; 300 mg /12.5 mg; 300 mg/25 mg).The recommended dose of Rasilez HCT is one tablet per day.
Croatian: Rasilez HCT izdaje se samo na recept i dostupan je u obliku tableta (150 mg/12,5 mg; 150 mg/25 mg; 300 mg/12,5 mg; 300 mg/25 mg).
English: Its use during the first three months of pregnancy is not recommended.
Croatian: Ne preporučuje se njegova primjena u prvom tromjesečju trudnoće.
English: Aliskiren on its own has been authorised in the EU since August 2007 as Rasilez, Sprimeo and Riprazo.
Croatian: Aliskiren kao monoterapija odobren je u EU-u od kolovoza 2007. kao Rasilez, Sprimeo i Riprazo.
English: Rasilez HCT is for use in adults only; it must not be used in children aged less than 2 years and is not recommended for older children.
Croatian: Rasilez HCT namijenjen je za liječenje samo odraslih; ne smiju ga uzimati djeca mlađa od 2 godine i ne preporučuje se za stariju djecu.
English: Taking the two active substances in one tablet is expected to help patients to stick to their treatment.
Croatian: Očekuje se da će primjena dviju djelatnih tvari u jednoj tableti pomoći bolesnicima da se pridržavaju terapije.
English: Side effects are similar to those of the two active substances.
Croatian: Nuspojave su slične onima koje nastaju zbog dvije djelatne tvari.
English: The studies lasted for between 8 weeks and a year, and the main measure of effectiveness was the change in blood pressure either during the resting phase of the heartbeat (diastolic) or when the chambers of the heart were contracting (systolic).
Croatian: Ispitivanja su trajala između 8 tjedana i godine dana, a glavna mjera učinkovitosti bila je promjena krvnog tlaka tijekom faze odmora između otkucaja srca (dijastolički) ili prilikom kontrakcije komora srca (sistolički).
English: Rasilez HCT should not be taken together with fruit juice or drinks containing plant extracts such as herbal teas.
Croatian: Rasilez HCT se ne smije uzimati s voćnim sokom ili pićima koja sadržavaju biljne ekstrakte kao što su biljni čajevi.
English: The company presented information used in the assessment of aliskiren and from the published literature to support its application for Rasilez HCT, as well as information from additional studies.
Croatian: Tvrtka je prikazala podatke upotrijebljene u procjeni aliskirena te iz objavljene literature kako bi potkrijepila svoj zahtjev za odobrenje lijeka Rasilez HCT kao i podatke iz dodatnih ispitivanja.
English: It blocks the activity of a human enzyme called renin, which is involved in the production of a substance called angiotensin I in the body.
Croatian: Blokira aktivnost ljudskog enzima pod nazivom renin koji sudjeluje u proizvodnji tvari pod nazivom angiotenzin I u tijelu.
English: Rasilez HCT (aliskiren / hydrochlorothiazide)
Croatian: Rasilez HCT (aliskiren / hidroklorotiazid)
English: Rasilez HCT received a marketing authorisation valid throughout the EU on 16 January 2009.
Croatian: Lijek Rasilez HCT dobio je odobrenje za stavljanje lijeka u promet koje je na snazi u Europskoj uniji od 16. siječnja 2009.
English: Side effects reported with Rasilez HCT are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Rasilez HCT pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: For more information about using Rasilez HCT, see the package leaflet or contact your doctor or pharmacist.
Croatian: Za više informacija o primjeni lijeka Rasilez HCT pogledajte uputu o lijeku ili se obratite liječniku ili ljekarniku.
English: It must not be taken with ciclosporin, itraconazole or other medicines known as ‘potent P-glycoprotein inhibitors' (such as quinidine).
Croatian: Ne smije se uzimati s ciklosporinom, itrakonazolom ili drugim lijekovima poznatima kao „snažni inhibitori P-glikoproteina” (kao što je kinidin).
English: The most common side effect with Rasilez HCT (which may affect between 1 and 10 patients in 100) is diarrhoea.
Croatian: Najčešća nuspojava lijeka Rasilez HCT (koja se može pojaviti u između 1 i 10 na 100 bolesnika) je proljev.
English: Angiotensin I is converted into the hormone angiotensin II, which is a powerful vasoconstrictor (a substance that narrows blood vessels).
Croatian: Angiotenzin I pretvara se u hormon angiotenzin II koji je snažan vazokonstriktor (tvar koja sužava krvne žile).
English: What measures are being taken to ensure the safe and effective use of Rasilez HCT?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Rasilez HCT?
English: Three additional studies showed that the active substances were absorbed in the body in the same way when taken as separate tablets and as Rasilez HCT.
Croatian: U trima dodatnim ispitivanjima pokazalo se da je tijelo apsorbiralo djelatne tvari jednako kada su uzimane kao zasebne tablete i kao Rasilez HCT.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rasilez HCT have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Rasilez HCT nalaze se u sažetku opisa svojstava i u uputi o lijeku.
English: What is Rasilez HCT and what is it used for?
Croatian: Što je Rasilez HCT i za što se koristi?
English: The European Medicines Agency decided that Rasilez HCT's benefits are greater than its risks and it can be authorised for use in the EU.
Croatian: Europska agencija za lijekove zaključila je da koristi od lijeka Rasilez HCT nadmašuju s njim povezane rizike te da se lijek može odobriti za primjenu u Europskoj uniji.
English: Most studies involved patients with mild to moderate hypertension and one involved patients with severe hypertension.
Croatian: Većina ispitivanja obuhvatila je bolesnike s blagom do umjerenom hipertenzijom, a jedno je ispitivanje obuhvatilo bolesnike s ozbiljnom hipertenzijom.
English: Results showed that Rasilez HCT was more effective than placebo in reducing blood pressure.
Croatian: Rezultati su pokazali da je Rasilez HCT učinkovitiji u snižavanju krvnog tlaka nego placebo.
English: Other information about Rasilez HCT
Croatian: Ostale informacije o lijeku Rasilez HCT
English: As for all medicines, data on the use of Rasilez HCT are continuously monitored.
Croatian: Kao za sve lijekove, podatci o primjeni lijeka Rasilez HCT kontinuirano se prate.
English: The studies compared the combination of aliskiren and hydrochlorothiazide with placebo (a dummy treatment), with aliskiren or hydrochlorothiazide taken alone, or with other medicines for hypertension (valsartan, irbesartan, lisinopril or amlodipine).
Croatian: U ispitivanjima je uspoređena kombinacija aliskirena i hidroklorotiazida s placebom (prividnim liječenjem), s monoterapijom aliskirenom ili hidroklorotiazidom, ili s drugim lijekovima protiv hipertenzije (valzartanom, irbesartanom, lizinoprilom ili amlodipinom).
English: The dose depends on the doses of aliskiren or hydrochlorothiazide that the patient was taking before.
Croatian: Doza ovisi o dozama aliskirena ili hidroklorotiazida koje je bolesnik prije uzimao.
English: Why is Rasilez HCT authorised in the EU?
Croatian: Zašto je lijek Rasilez HCT odobren u EU-u?
English: The two active substances in Rasilez HCT, aliskiren and hydrochlorothiazide, work in different ways to reduce blood pressure.
Croatian: Dvije djelatne tvari u lijeku Rasilez HCT, aliskiren i hidroklorotiazid, djeluju na različite načine i dovode do sniženja krvnog tlaka.
English: Other common side effects (which may affect more than 1 in 10 patients) that have been observed with hydrochlorothiazide alone are hypokalaemia (low blood potassium levels) and increases in blood cholesterol and triglyceride (a type of fat) levels.
Croatian: Druge česte nuspojave (mogu se pojaviti u više od 1 na 10 bolesnika), koje su opažene uz hidroklorotiazid koji se uzima kao monoterapija, bile su hipokalijemija (niske razine kalija u krvi) i povišenje razine kolesterola i triglicerida (vrsta masti) u krvi.
English: By lowering blood pressure, the risk caused by high blood pressure, such as having a stroke, is reduced.
Croatian: Snižavanjem krvnog tlaka smanjuje se i rizik koji uzrokuje visoki krvi tlak, kao što je rizik od moždanog udara.
English: Patients previously taking only aliskiren or hydrochlorothiazide may need to take the two substances as separate tablets and adjust the doses before switching to Rasilez HCT.
Croatian: Bolesnici koji su prethodno uzimali samo aliskiren ili hidroklorotiazid možda će morati uzimati dvije tvari kao zasebne tablete te prilagoditi doze prije prelaska na Rasilez HCT.
English: Rasilez HCT must not be used in patients who have had angioedema (swelling under the skin) with aliskiren, hereditary angioedema or angioedema of no obvious cause, who have anuria (a condition in which a patient cannot make or pass urine), severe kidney or liver impairment, or whose blood potassium levels are too low or blood calcium levels are too high.
Croatian: Rasilez HCT ne smiju uzimati bolesnici koji su uz primjenu aliskirena imali angioedem (oticanje ispod kože), nasljedni angioedem ili angioedem bez očitog uzroka, bolesnici koji imaju anuriju (stanje u kojem tijelo bolesnika ne može stvarati ili izlučivati mokraću), teško oštećenje bubrega ili jetre, ili u onih u kojih su razine kalija u krvi preniske ili razine kalcija u krvi previsoke.
English: Rasilez HCT is used in patients whose blood pressure is not adequately controlled by aliskiren or hydrochlorothiazide taken alone.
Croatian: Rasilez HCT primjenjuje se u bolesnika čiji se krvni tlak ne kontrolira na odgovarajući način primjenom samo aliskirena ili samo hidroklorotiazida.
English: It works by increasing urine output, reducing the amount of fluid in the blood and reducing blood pressure.
Croatian: Djeluje tako da povećava izlučivanje mokraće, čime se smanjuje količina tekućine u krvi i snižava krvni tlak.
English: What are the risks associated with Rasilez HCT?
Croatian: Koji su rizici povezani s lijekom Rasilez HCT?
English: An overview of Rasilez HCT and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Rasilez HCT i zašto je odobren u EU-u
English: In patients whose blood pressure was not adequately controlled on either aliskiren or hydrochlorothiazide alone, switching to the combination resulted in greater falls in blood pressure than remaining on one active substance alone.
Croatian: U bolesnika u kojih se krvni tlak nije kontrolirao na odgovarajući način samo aliskirenom ili hidroklortiazidom, prijelaz na kombinaciju rezultirao je većim sniženjem krvnog tlaka nego daljnja primjena samo jedne djelatne tvari.
English: The medicine contains the active substances aliskiren and hydrochlorothiazide.
Croatian: Lijek sadrži djelatne tvari aliskiren i hidroklorotiazid.
English: The combination of the two active substances has an additive effect, reducing the blood pressure more than either medicine alone.
Croatian: Kombinacijom dviju djelatnih tvari učinak se pojačava što snižava krvni tlak više nego svaki lijek zasebno.
English: It can also be used in patients whose blood pressure is adequately controlled with aliskiren and hydrochlorothiazide taken as separate tablets, to replace the same doses of the two active substances.
Croatian: Također ga mogu uzimati bolesnici čiji se krvni tlak na odgovarajući način kontrolira primjenom aliskirena ili hidroklorotiazida koji se uzimaju kao odvojene tablete, kako bi se zamijenile jednake doze dviju djelatnih tvari.
English: The medicine has been shown to reduce blood pressure more than each active substance alone.
Croatian: Pokazalo se da ovaj lijek snižava krvni tlak više nego svaka djelatna tvar zasebno.
English: After two to four weeks of taking Rasilez HCT, the dose can be increased in patients whose blood pressure remains uncontrolled.
Croatian: U bolesnika u kojih uz primjenu lijeka Rasilez HCT u trajanju od dva do četiri tjedna krvni tlak i dalje nije odgovarajuće kontroliran, dozu se može povisiti.
English: In patients already adequately controlled with the two active substances, the dose of Rasilez HCT must contain the same doses of aliskiren and hydrochlorothiazide that the patient was taking before.
Croatian: U bolesnika čiji se krvni tlak na odgovarajući način kontrolira dvjema djelatnim tvarima, doza lijeka Rasilez HCT mora sadržavati doze aliskirena i hidroklorotiazida jednake onima koje je bolesnik prije uzimao.
English: Rasilez HCT is a medicine used to treat essential hypertension (high blood pressure) in adults.
Croatian: Rasilez HCT je lijek za liječenje esencijalne hipertenzije (visoki krvni tlak) u odraslih. „Esencijalna” hipertenzija znači da se ne može ustanoviti točan uzrok hipertenzije.
English: How does Rasilez HCT work?
Croatian: Kako djeluje Rasilez HCT?
English: For the full list of all side effects reported with Rasilez HCT, see the package leaflet.
Croatian: Potpuni popis svih nuspojava zabilježenih pri primjeni lijeka Rasilez HCT potražite u uputi o lijeku.
English: By blocking the production of angiotensin I, levels of both angiotensin I and angiotensin II fall.
Croatian: Onemogućavanjem stvaranja angiotenzina I, snižavaju se razine i angiotenzina
English: How is Rasilez HCT used?
Croatian: Kako se Rasilez HCT koristi?
English: Rasilez HCT in combination with an ‘angiotensin converting enzyme (ACE) inhibitors' or ‘angiotensin receptor blockers' (ARBs) must not be used in patients with diabetes,
Croatian: Rasilez HCT ne smije se primjenjivati u kombinaciji s inhibitorima angiotenzin konvertirajućeg enzima ili blokatorima receptora angiotenzina u bolesnika s dijabetesom ili umjerenim ili teškim oštećenjem bubrega.
English: What benefits of Rasilez HCT have been shown in studies?
Croatian: Koje su koristi od lijeka Rasilez HCT utvrđene u ispitivanjima?
English: This overview was last updated in December 2018.
Croatian: Pregled informacija posljednji je put ažuriran u prosincu 2018.
English: Further information on Melosus can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/melosus.
Croatian: Više informacija o VMP-u Melosus nalazi se na internetskim stranicama Agencije: ema.europa.eu/medicines/veterinary/EPAR/melosus.
English: What is Melosus and what is it used for?
Croatian: Što je Melosus i za što se koristi?
English: Previously known as Melocam.
Croatian: Prethodno poznat kao Melocam.
English: Melosus is available as an oral (taken by mouth) suspension as 0.5 mg/ml for use in cats and guinea pigs and 1.5 mg/ml for use in dogs.
Croatian: Melosus je dostupan u obliku peroralne suspenzije (primjenjuje se kroz usta) od 0,5 mg/ml za primjenu u mačaka i zamorčadi te od 1,5 mg/ml za primjenu u pasa.
English: The dose depends on the animal, the bodyweight and condition and is given mixed with food or directly into the mouth for dogs and cats and directly into the mouth for guinea pigs.
Croatian: Doza ovisi o životinji, njezinoj tjelesnoj težini i stanju, a daje se pomiješana s hranom ili izravno u usta u pasa i mačaka te izravno u usta u zamorčadi.
English: Melosus received a marketing authorisation valid throughout the EU on21 February 2011.
Croatian: Za VMP Melosus izdano je odobrenje za stavljanje u promet koje je na snazi u Europskoj uniji od 21. veljače 2011.
English: As for every medicine, the company provided studies on the quality of Melosus.
Croatian: Kao i za svaki VMP, tvrtka je dostavila ispitivanja o kvaliteti VMP-a Melosus.
English: This means that Melosus contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Metacam.
Croatian: To znači da Melosus sadržava istu djelatnu tvar i djeluje na isti način kao i „referentni VMP” koji je već odobren u Europskoj uniji (EU) pod nazivom Metacam.
English: Other information about Melosus
Croatian: Ostale informacije o VMP-u Melosus
English: What are the benefits and risks of Melosus?
Croatian: Koje su koristi i rizici VMP-a Melosus?
English: Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Metacam, and do not need to be repeated for Melosus.
Croatian: Ispitivanja omjera koristi i rizika djelatne tvari u odobrenim primjenama već su provedena s referentnim VMP-om Metacam i stoga ih nije potrebno ponavljati za VMP Melosus.
English: An overview of Melosus and why it is authorised in the EU
Croatian: Pregled informacija o VMP-u Melosus i zašto je odobren u EU-u
English: Melosus (meloxicam)1
Croatian: Melosus (meloksikam)
English: The European Medicines Agency concluded that, in accordance with EU requirements, Melosus has been shown to have comparable quality and to be bioequivalent to Metacam.
Croatian: Europska agencija za lijekove zaključila je kako je, u skladu sa zahtjevima EU-a, utvrđeno da VMP Melosus posjeduje usporedivu kakvoću te da je bioekvivalentan VMP-u Metacam.
English: Melosus is an anti-inflammatory medicine used in dogs, cats and guinea pigs.
Croatian: Melosus je protuupalni lijek koji se primjenjuje u pasa, mačaka i zamorčadi.
English: Why is Melosus authorised in the EU?
Croatian: Zašto je VMP Melosus odobren u EU-u?
English: Melosus contains meloxicam, which belongs to a class of medicines called non-steroidal antiinflammatory drugs (NSAIDs).
Croatian: Melosus sadržava meloksikam, koji pripada skupini lijekova zvanih nesteroidni protuupalni lijekovi (NSPUL).
English: As prostaglandins trigger inflammation, pain, exudation (fluid that leaks out of blood vessels during an inflammation) and fever, meloxicam reduces these signs of inflammation.
Croatian: S obzirom na to da su prostaglandini tvari koje potiču upalu, bol, eksudaciju (curenje tekućine iz krvnih žila tijekom upale) i vrućicu, meloksikam smanjuje te znakove upale.
English: Melosus can only be obtained with a prescription.
Croatian: Melosus se izdaje samo na veterinarski recept.
English: Therefore, the Agency's view was that, as for Metacam, the benefit of Melosus outweighs the identified risk and it can be authorised for use in the EU.
Croatian: Stoga je mišljenje Agencije da korist od VMP-a Melosus, kao i od VMP-a Metacam, nadmašuje utvrđeni rizik te se može izdati odobrenje za njegovu primjenu u EU-u.
English: Moreover, it is used to lessen pain and inflammation in chronic musculo-skeletal disorders.
Croatian: Nadalje, primjenjuje se za olakšavanje bolova i upale kod kroničnih mišićno-koštanih poremećaja.
English: Because Melosus is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Croatian: Budući da je Melosus generički VMP te je bioekvivalentan referentnom VMP-u, smatra se da su njegove koristi i rizici isti kao i oni referentnog VMP-a.
English: For further information about using Melosus, see the package leaflet or contact your veterinarian or pharmacist.
Croatian: Za dodatne informacije o primjeni VMP-a Melosus pogledajte uputu o VMP-u, odnosno obratite se veterinaru ili ljekarniku.